Gt Biopharma Stock Buy Hold or Sell Recommendation
| GTBP Stock | USD 3.19 0.06 1.85% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding GT Biopharma is 'Strong Sell'. Macroaxis provides GT Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GTBP positions. The advice algorithm takes into account all of GT Biopharma's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting GT Biopharma's buy or sell advice are summarized below:
Real Value 3.97 | Target Price 5 | Hype Value 3.22 | Market Value 3.19 | Naive Value 3.27 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell GT Biopharma given historical horizon and risk tolerance towards GT Biopharma. When Macroaxis issues a 'buy' or 'sell' recommendation for GT Biopharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
GTBP |
Execute GT Biopharma Buy or Sell Advice
The GTBP recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on GT Biopharma. Macroaxis does not own or have any residual interests in GT Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute GT Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
GT Biopharma Trading Alerts and Improvement Suggestions
| GT Biopharma generated a negative expected return over the last 90 days | |
| GT Biopharma has high historical volatility and very poor performance | |
| GT Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GT Biopharma currently holds about 23.73 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Heres Why GT Biopharma, Inc. Is a Great Buy the Bottom Stock Now - Yahoo News Australia |
GT Biopharma Returns Distribution Density
The distribution of GT Biopharma's historical returns is an attempt to chart the uncertainty of GT Biopharma's future price movements. The chart of the probability distribution of GT Biopharma daily returns describes the distribution of returns around its average expected value. We use GT Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of GT Biopharma returns is essential to provide solid investment advice for GT Biopharma.
| Mean Return | -0.46 | Value At Risk | -9.79 | Potential Upside | 9.04 | Standard Deviation | 5.71 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of GT Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
GTBP Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GT Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GT Biopharma backward and forwards among themselves. GT Biopharma's institutional investor refers to the entity that pools money to purchase GT Biopharma's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2023-12-31 | 95.2 K | Simplex Trading, Llc | 2023-12-31 | 304 | Blue Bell Private Wealth Management, Llc | 2023-12-31 | 300 | Advisory Services Network, Llc | 2023-12-31 | 150 | Front Row Advisors Llc | 2023-12-31 | 58.0 | Baskin Financial Services Inc | 2023-12-31 | 0.0 | Susquehanna International Group, Llp | 2023-12-31 | 0.0 | Welch Group, Llc | 2024-03-31 | 0.0 | Sigma Planning Corp | 2023-12-31 | 0.0 | Fmr Inc | 2023-12-31 | 0.0 | Compagnie Lombard, Odier Sca | 2023-12-31 | 0.0 |
GT Biopharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (32K) | 5.3M | 3.7M | (3.3M) | (4.6M) | (4.4M) | |
| Free Cash Flow | (3.7M) | (7.3M) | (15.6M) | (15.2M) | (8.9M) | (8.4M) | |
| Other Non Cash Items | 1.6M | 18.4M | 538K | 10K | (5.3M) | (5.0M) | |
| Net Income | (38.6M) | (28.3M) | (58.0M) | (20.9M) | (7.6M) | (8.0M) | |
| End Period Cash Flow | 28K | 5.3M | 9.0M | 5.7M | 1.1M | 1.4M | |
| Net Borrowings | 10.7M | 3.4M | 12.5M | 1.2M | 1.4M | 1.3M | |
| Change To Netincome | 238.7M | 31.5M | 18.3M | 34.5M | 39.6M | 64.7M | |
| Investments | (36K) | 200K | (23.0M) | 12.1M | 5.0M | 5.3M |
GT Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to GT Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that GT Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a GTBP stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.47 | |
β | Beta against NYSE Composite | -0.04 | |
σ | Overall volatility | 5.38 | |
Ir | Information ratio | -0.1 |
GT Biopharma Volatility Alert
GT Biopharma exhibits very low volatility with skewness of 0.63 and kurtosis of 2.05. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure GT Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact GT Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.GT Biopharma Fundamentals Vs Peers
Comparing GT Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze GT Biopharma's direct or indirect competition across all of the common fundamentals between GT Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as GT Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of GT Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing GT Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare GT Biopharma to competition |
| Fundamentals | GT Biopharma | Peer Average |
| Return On Equity | -0.79 | -0.31 |
| Return On Asset | -0.55 | -0.14 |
| Current Valuation | (9.5 M) | 16.62 B |
| Shares Outstanding | 1.38 M | 571.82 M |
| Shares Owned By Insiders | 10.41 % | 10.09 % |
| Shares Owned By Institutions | 90.50 % | 39.21 % |
| Number Of Shares Shorted | 5.97 K | 4.71 M |
| Price To Book | 0.62 X | 9.51 X |
| EBITDA | (13.58 M) | 3.9 B |
| Net Income | (7.6 M) | 570.98 M |
| Cash And Equivalents | 23.73 M | 2.7 B |
| Cash Per Share | 0.76 X | 5.01 X |
| Total Debt | 58 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 2.78 X | 2.16 X |
| Book Value Per Share | 5.41 X | 1.93 K |
| Cash Flow From Operations | (8.85 M) | 971.22 M |
| Short Ratio | 0.81 X | 4.00 X |
| Earnings Per Share | (5.58) X | 3.12 X |
| Target Price | 150.0 | |
| Number Of Employees | 2 | 18.84 K |
| Beta | 0.66 | -0.15 |
| Market Capitalization | 4.29 M | 19.03 B |
| Total Asset | 14.11 M | 29.47 B |
| Retained Earnings | (682.07 M) | 9.33 B |
| Working Capital | 7.42 M | 1.48 B |
| Net Asset | 14.11 M |
Note: Insider Trading [view details]
GT Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as GTBP . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About GT Biopharma Buy or Sell Advice
When is the right time to buy or sell GT Biopharma? Buying financial instruments such as GTBP Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 138K | 1.7M | 2.2M | 2.3M | Total Assets | 32.2M | 16.7M | 14.1M | 13.2M |
Use Investing Ideas to Build Portfolios
In addition to having GT Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals ETFs Thematic Idea Now
Precious Metals ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Precious Metals ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out GT Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for GTBP Stock analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is GT Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.58) | Return On Assets (0.55) | Return On Equity (0.79) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.